Early Detection
415 articles
Could There Be a Cure in Vitamin C?
Vitamin C has been found to kill cancer cells that carry the KRAS mutation. This mutation is common in pancreatic and colorectal cancers.
Fighting Pancreatic Cancer in a Petri Dish
Dr. David Tuveson is growing pancreatic cancer tissue called organoids in the lab, to test which drugs will be most effective against a patient’s tumor.
Solving the Mystery of Cachexia
Researchers are looking for ways to combat cachexia, the metabolic syndrome that causes weight and muscle loss in people with cancer and other diseases.
Clinical Trial of Immunotherapy Plus Sunshine Vitamin May Help in Pancreatic Cancer Fight
Can vitamin D make it easier for chemotherapy drugs to reach the pancreatic cancer tumor? A clinical trial is testing this idea.
Testing Vitamin C as a Cancer Killer
Lewis Cantley’s team is starting clinical trials of vitamin C to gain more information about its role in stopping cancer.
Targeted Therapy for Pancreatic Cancer
Dr. Margaret Tempero outlines the work being done in the area of targeted therapy for pancreatic cancer, specifically the testing of ibrutinib.
Predicting Effective Therapy in Pancreatic Cancer
Dr. Kenneth Yu is leading a clinical trial that looks at a pancreatic cancer patient’s pharmacogenomic profile, to see which chemotherapy works better.
Standard of Care Plus
Dr. Allyson Ocean explains why pancreatic cancer patients should consider clinical trials, which go beyond standard of care.
The ABCs of Genetic Testing
There are a number of different genetic mutations that can cause familial pancreatic cancer. This article explains some of the most common ones.
Neoantigens Provide New Hope for Pancreatic Cancer Treatments
Vinod Balachandran’s team identified increased T cells in the tumors of long-term pancreatic cancer survivors, with a role for neoantigens in immunotherapy.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
The Promise of Organoids
Dr. Brian Wolpin explains how organoids are being used to develop personalized treatment for pancreatic cancer patients.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.